Table 1. Baseline characteristics n a... | Rockefeller University Press

Table 1.

Baseline characteristics

	n^{^a}
Female	24 (50%)
Deceased	3 (6.3%)
Hematopoietic stem cell transplantation	10 (21%)
TNF inhibitor treatment	37 (77%)
Biallelic ADA2 variant	46 (96%)
ADA2 activity available	35 (73%)
	Median (range)^{^b}
Age at onset [years]	4.0 (0.08–43)
Age at diagnosis [years]	15 (0.5–50)
Age at last follow-up [years]	17.5 (3–57)
Diagnostic delay [years]	7.8 (0–42)
ADA2 activity [mU/g]	2.0 (0–19)
ADA2 activity [mU/ml]	0.56 (0.24–0.68)

	n^a
Female	24 (50%)
Deceased	3 (6.3%)
Hematopoietic stem cell transplantation	10 (21%)
TNF inhibitor treatment	37 (77%)
Biallelic ADA2 variant	46 (96%)
ADA2 activity available	35 (73%)
	Median (range)^b
Age at onset [years]	4.0 (0.08–43)
Age at diagnosis [years]	15 (0.5–50)
Age at last follow-up [years]	17.5 (3–57)
Diagnostic delay [years]	7.8 (0–42)
ADA2 activity [mU/g]	2.0 (0–19)
ADA2 activity [mU/ml]	0.56 (0.24–0.68)

Baseline data given as number (percent) of patients.

Baseline information given as median (range) on age, diagnosis, and ADA2 activity.